Journal of Clinical & Experimental Pharmacology

Zeng Y

Publications

• Research Article
  Combination of Nab-Paclitaxel with Trastuzumab as Neoadjuvant Chemotherapy for HER2-positive Breast Cancer Patients: Experience from a Single Center
  Author(s): Li T, Yang M, Ren C, Lao H and Zeng YLi T, Yang M, Ren C, Lao H and Zeng Y
  
  Background: Several phase II and pilot studies showed that neoadjuvant nab-paclitaxel-based chemotherapy and trastuzumab treatment was effective and safe. However, combination of nab-paclitaxel alone with trastuzumab has not been investigated. Methods: This is a retrospective analysis. From July 2009 to June 2014, Patients with histologically confirmed, nonmetastatic HER2-positive breast cancer who received a 3-week regimen of nab-paclitaxel with trastuzumab in Guangdong General Hospital were screened. Baseline and pathological data and blood test results were collected from the electronic patient medical records. Survival data, severe adverse events and cardiac events were collected by telephone follow-up. The primary endpoint was pCR. The secondary endpoints included pCR in breast, DFS during follow-up period, breast conserving rates, tolerance, adverse events and symptomatic cardiac e.. View More»
  DOI: 10.4172/2161-1459.1000209

  Abstract PDF